Xencor: Bullish On Their Increasingly In-House Pipeline

Xencor is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology. Read more on XNCR stock here.

Xencor, Inc. (XNCR) is an antibody-focused biotechnology company with a business model increasingly shifting from its established technology-licensing model toward a broader portfolio of wholly owned pipeline assets. The company’s platform is XmAb, and it has Summary - Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology. -

The upcoming XmAb819 and XmAb541 dose-selection data will soon clarify whether XNCR’s oncology assets can become pivotal candidates. - XmAb942 is probably their most important catalyst over the long term. The earlier-stage autoimmune programs should help sustain XNCR’s valuation in the near term.

- I believe XNCR’s balance sheet is enough to finance its near-term milestones. The wildcard is how much cash burn increases once pivotal trials commence. - Ultimately, I remain bullish on the stock because XNCR has several programs that can create significant shareholder value if successful.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha).

I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor.

Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party